| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Snr. VP, Chem and Non-clin Dev
1 company
Zhen Li is Snr. VP, Chem and Non-clin Dev at ARWR. Zhen Li's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $12.0M at current prices.
The ARWR filings lean toward selling, a net 40,500 shares.
Zhen Li has 3 Form 4 filings on record from January 2019 to September 2026, across 2 companies: President and CEO at ADARx Pharmaceuticals (ADRX), 2026; Snr. VP, Chem and Non-clin Dev at Arrowhead Pharmaceuticals (ARWR), 2019.
The 3 reported transactions were 1 option or other derivative award, 1 open-market sale and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $581K.
The only open-market sale was 40,500 shares of ARWR at an average $14.34 on January 14, 2019, about $581K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 14, 2019 | ARWR Arrowhead Pharmaceuticals, Inc. | Snr. VP, Chem and Non-clin Dev | Sell | 40,500 | $14.34 | $580,770.00 | -16.7% |